LBLTF (Lattice Biologics) Beginning Cash Position: $-0.00 Mil (As of Jun. 2021)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Lattice Biologics Beginning Cash Position?

Lattice Biologics LBLTF -99.00% Beginning Cash Position is $-0.00 Mil as of Jun. 2021.

Lattice Biologics's Beginning Cash Position for the quarter that ended in Jun. 2021 was $-0.00 Mil.

Lattice Biologics's quarterly Beginning Cash Position declined from Dec. 2020 ($0.06 Mil) to Mar. 2021 ($-0.00 Mil) but then increased from Mar. 2021 ($-0.00 Mil) to Jun. 2021 ($-0.00 Mil).

Lattice Biologics's annual Beginning Cash Position declined from Sep. 2018 ($0.02 Mil) to Sep. 2019 ($0.01 Mil) but then increased from Sep. 2019 ($0.01 Mil) to Sep. 2020 ($0.02 Mil).

Lattice Biologics Beginning Cash Position Related Terms

Lattice Biologics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Lattice Biologics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lattice Biologics Beginning Cash Position Chart

Lattice Biologics Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Sep16 Sep17 Sep18 Sep19 Sep20
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.05 0.02 0.01 0.02

Lattice Biologics Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.06 -0.00 -0.00

Lattice Biologics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $-0.00 Mil mean?
Lattice Biologics (LBLTF) has a Beginning Cash Position of $-0.00 Mil as of Jun. 2021. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Lattice Biologics and its competitors.
Is Lattice Biologics' Beginning Cash Position too high?
Lattice Biologics' current Beginning Cash Position is $-0.00 Mil.
How does Lattice Biologics' Beginning Cash Position compare to ABT and MDT?
Lattice Biologics' Beginning Cash Position of $-0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Devices & Instruments company?
A good Beginning Cash Position depends on the Medical Devices & Instruments industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Lattice Biologics and its competitors. Lattice Biologics's current Beginning Cash Position is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lattice Biologics stock overvalued right now?
Lattice Biologics (LBLTF) has a current Beginning Cash Position of $-0.00 Mil. The current Beginning Cash Position is $-0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Lattice Biologics (LBLTF), the current Beginning Cash Position is $-0.00 Mil as of Jun. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lattice Biologics Business Description

Address 512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714
Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The company's products include ADM dermis, DBM Putty, Bone scaffold, and others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.